Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MURALI M CHAKINALA

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1407872724
CMS profile
245533
Location
SAINT LOUIS, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$51,406.05

63 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $37,522.50 7
Travel and Lodging $11,343.66 14
Food and Beverage $2,539.89 42

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–63 of 63 matching records. This page contains 13 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MURALI M CHAKINALA

NPI 1407872724 · CMS profile ID 245533

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

SAINT LOUIS, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–63 of 63 matching records. This page contains 13 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1407872724?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MURALI M CHAKINALA, NPI 1407872724, CMS profile ID 245533. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–63 of 63 matching records. This page contains 13 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1407872724?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). MURALI M CHAKINALA, NPI 1407872724, CMS profile ID 245533. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–63 of 63 matching records. This page contains 13 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1407872724?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
MURALI M CHAKINALA, NPI 1407872724, CMS profile ID 245533, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–63 of 63 matching records. This page contains 13 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1407872724?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

63 matching records · $51,406.05 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 63 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–63 of 63.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Sandoz Inc. $22.1802/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089369436 CMS
Merck Sharp & Dohme LLC $150.0002/12/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141818469 CMS
Merck Sharp & Dohme LLC $7,320.0002/12/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141818661 CMS
Merck Sharp & Dohme LLC $253.9602/05/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141888279 CMS
Merck Sharp & Dohme LLC $32.7602/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141753228 CMS
Merck Sharp & Dohme LLC $16.7602/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141753238 CMS
Merck Sharp & Dohme LLC $257.5102/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141753240 CMS
Merck Sharp & Dohme LLC $7,971.7002/03/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141753242 CMS
Merck Sharp & Dohme LLC $257.5102/03/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141753244 CMS
Merck Sharp & Dohme LLC $203.1702/03/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141753246 CMS
Merck Sharp & Dohme LLC $127.5002/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141756644 CMS
United Therapeutics Corporation $124.9701/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149461090 CMS
Janssen Scientific Affairs, LLC $5,375.0001/23/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078862537 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $17,807.04 44
PY2020 $21,462.49 13
PY2021 $5,368.95 12
PY2022 $14,751.24 35
PY2023 $21,799.28 33
PY2024 $51,406.05 63
PY2025 $39,639.97 74

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $193,147.66 29
PY2024 Principal investigator $360,987.26 37
PY2023 Principal investigator $442,162.82 34
PY2022 Principal investigator $407,673.44 62
PY2021 Principal investigator $246,073.83 53
PY2020 Principal investigator $238,601.13 35
PY2019 Principal investigator $378,598.00 29

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

29 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $77,829.62 12/31/2025 Non-covered Recipient Entity
Washington University School of Medicine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension PAH World Health Organization WHO Functional Class FC III o No dispute reported 06/30/2026 1232937016
Principal investigator 1 Merck Sharp & Dohme LLC $59,290.09 12/31/2025 Non-covered Recipient Entity
Washington University School of Medicine
A Phase 3, Randomized Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients No dispute reported 06/30/2026 1232938602
Principal investigator 1 Janssen Research & Development, LLC $500.00 12/26/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY SCHOOL OF MED
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175367676
Principal investigator 1 United Therapeutics Corporation $3,803.40 12/17/2025 Non-covered Recipient Entity
THE WASHINGTON UNIVERSITY
A STUDY EVALUATING THE LONG-TERM EFFICACY AND SAFETY OF RALINEPAG IN SUBJECTS WITH PAH VIA AN OPEN-LABEL EXTENSION No dispute reported 06/30/2026 1242390477
Principal investigator 1 United Therapeutics Corporation $637.20 12/15/2025 Non-covered Recipient Entity
THE WASHINGTON UNIVERSITY
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION No dispute reported 06/30/2026 1242390457
Principal investigator 1 Janssen Research & Development, LLC $640.00 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY SCHOOL OF MED
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175367698
Principal investigator 1 United Therapeutics Corporation $4,070.70 11/20/2025 Non-covered Recipient Entity
THE WASHINGTON UNIVERSITY
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION No dispute reported 06/30/2026 1242390467
Principal investigator 1 Janssen Research & Development, LLC $320.00 10/27/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY SCHOOL OF MED
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175367520
Principal investigator 1 Janssen Research & Development, LLC $6,911.00 09/22/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY SCHOOL OF MED ICINE
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175367487
Principal investigator 1 United Therapeutics Corporation $7,486.00 09/22/2025 Non-covered Recipient Entity
THE WASHINGTON UNIVERSITY
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION No dispute reported 06/30/2026 1242390469
Principal investigator 1 United Therapeutics Corporation $1,500.00 09/10/2025 Non-covered Recipient Entity
THE WASHINGTON UNIVERSITY
A STUDY EVALUATING THE LONG-TERM EFFICACY AND SAFETY OF RALINEPAG IN SUBJECTS WITH PAH VIA AN OPEN-LABEL EXTENSION No dispute reported 06/30/2026 1242390473
Principal investigator 1 Janssen Research & Development, LLC $320.00 09/04/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY SCHOOL OF MED ICINE
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175367565
Principal investigator 1 United Therapeutics Corporation $3,070.80 08/13/2025 Non-covered Recipient Entity
THE WASHINGTON UNIVERSITY
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION No dispute reported 06/30/2026 1242390465
Principal investigator 1 Janssen Research & Development, LLC $130.00 08/11/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY SCHOOL OF MED ICINE
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175367294
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 07/28/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY SCHOOL OF MED ICINE
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175367778
Principal investigator 1 Janssen Research & Development, LLC $640.00 06/26/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY SCHOOL OF MED ICINE
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175367753
Principal investigator 1 United Therapeutics Corporation $3,070.80 06/18/2025 Non-covered Recipient Entity
THE WASHINGTON UNIVERSITY
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION No dispute reported 06/30/2026 1242390463
Principal investigator 1 United Therapeutics Corporation $2,108.00 06/13/2025 Non-covered Recipient Entity
THE WASHINGTON UNIVERSITY
A STUDY EVALUATING THE LONG-TERM EFFICACY AND SAFETY OF RALINEPAG IN SUBJECTS WITH PAH VIA AN OPEN-LABEL EXTENSION No dispute reported 06/30/2026 1242390475
Principal investigator 1 Merck Sharp & Dohme LLC $2,230.74 06/05/2025 Non-covered Recipient Entity
Barnes-Jewish Hospital Center for Outpatient Health
An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy for the Treatment of PAH No dispute reported 06/30/2026 1232917631
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,501.05 06/01/2025 Non-covered Recipient Entity
John L Trotter Multiple Sclerosis Center At Washu Medicine
BAY 632521, RiOciguAt UseRs Registry The ROAR registry No dispute reported 06/30/2026 1225419767
Principal investigator 1 Janssen Research & Development, LLC $640.00 05/26/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY SCHOOL OF MED ICINE
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175367326
Principal investigator 1 United Therapeutics Corporation $1,000.00 04/11/2025 Non-covered Recipient Entity
THE WASHINGTON UNIVERSITY
A STUDY EVALUATING THE LONG-TERM EFFICACY AND SAFETY OF RALINEPAG IN SUBJECTS WITH PAH VIA AN OPEN-LABEL EXTENSION No dispute reported 06/30/2026 1242390471
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 03/03/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY SCHOOL OF MED ICINE
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175367669
Principal investigator 1 Janssen Research & Development, LLC $1,020.00 02/24/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY SCHOOL OF MED ICINE
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175367793
Principal investigator 1 United Therapeutics Corporation $2,593.80 02/19/2025 Non-covered Recipient Entity
THE WASHINGTON UNIVERSITY
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION No dispute reported 06/30/2026 1242390461
Principal investigator 1 Merck Sharp & Dohme LLC $478.86 02/06/2025 Non-covered Recipient Entity
Washington University School of Medicine
A Phase 3, Randomized Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients No dispute reported 06/30/2026 1232938604
Principal investigator 1 Janssen Research & Development, LLC $640.00 01/27/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY SCHOOL OF MED ICINE
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175367416
Principal investigator 1 United Therapeutics Corporation $795.60 01/22/2025 Non-covered Recipient Entity
THE WASHINGTON UNIVERSITY
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION No dispute reported 06/30/2026 1242390459
Principal investigator 1 Janssen Research & Development, LLC $4,920.00 01/13/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Prospective Multi Center double blind randomized active controlled triple dummy parallel group sequential adaptive Phase 3 clinical study to compare the efficacy and safety of macitentan and tadalafil monotherapies with the corresponding fixed dose combination in subjects with pulmonary arterial hypertension PAH followed by an open label treatment period with macitentan and tadalafil fixed dose combination therapy No dispute reported 06/30/2026 1175368215